AMicale des COXiens

Forum des actionnaires particuliers de NicOx
 
AccueilAccueil  GalerieGalerie  S'enregistrerS'enregistrer  ConnexionConnexion  

Partagez | 
 

 nouvelle embauche chez NicOx ! Jennifer Collins Associate Br

Voir le sujet précédent Voir le sujet suivant Aller en bas 
AuteurMessage
Invité
Invité



MessageSujet: nouvelle embauche chez NicOx ! Jennifer Collins Associate Brand Director at NicOx   Sam 16 Jan - 19:33

ce mois-ci :

Jennifer Collins
Associate Brand Director at NicOx
Greater New York City Area Pharmaceuticals
Poste actuel
Associate Brand Director chez NicOx
Postes précédents
Associate Director chez Savient Pharmaceuticals
Senior Product Manager chez The Medicines Company
Marketing Manager chez GE Healthcare
tout voir...
Formation
University of Phoenix
University of Alabama at Birmingham
Gadsden State Community College

Pharmaceutical professional with 8+ years of marketing experience with focus on launching new in-line product indications and products, new marketing campaigns and positioning, product development, market research, and life cycle management to support the profitability of the brand, 3 years of pharmaceutical sales experience with proven performance, and 6.5 years of clinical experience in radiology and nursing. Knowledge-based leader with demonstrated talent to coach, mentor, and train. Dedicated team player—both as a leader and member of cross-functional and cross-cultural teams. Demonstrated proficiency in seeing the big picture, and being proactive to resolve complex problems, develop strategies, and deliver comprehensive solutions fully aligned with the customer’s needs.

Compétences
advertising, benchmarking, brand management, brochure design, budgeting, communication skills, continuous improvement, directing, editing, executive management, finance, inventory management, leadership, listening, market planning, market research, marketing, materials management, meeting facilitation, messaging, nursing, packaging, positioning, press releases, pricing, product management, profit, promotional materials, public relations, sales, strategic marketing,
Revenir en haut Aller en bas
Invité
Invité



MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 13:18

bon cette chère Jennifer travaillait chez Savient Pharma il y a un mois ... et que fait cette boîte hein ???
douleurs, rhumato un produit commercialisé et une phase III en route, de plus ils cherchent un partenaire :

home
At Savient, the expansion of our product portfolio is a strategic focus over the next few years. To this end, we are actively pursuing two directions:

Partnering Puricase®
We seek to form alliances with potential development and commercialization partners for Puricase, our late stage Phase 3 product, that will accelerate our time to market and extend our geographic reach in global markets outside the United States. We currently remain open to structures that include regional partnerships or a single partner who has demonstrated abilities to develop and market on a global scale.

In- Licensing or Product Acquisition
We are seeking opportunities to expand our product pipeline beyond Puricase and evaluate licensing and acquisition opportunities involving innovative clinical stage or marketed drug candidates that address unmet medical needs, offer excellent market potential and provide synergies with our business model with a specific interest in rheumatology and nephrology. We are also interested in autoimmune, endocrine and infectious diseases, along with urology, GI and neurology in which we can commercialize effectively with a targeted specialty sales force.

Our process for identifying and assessing opportunities is proactive and disciplined. Specifically, we seek opportunities that match our scientific, development and commercialization strengths. We evaluate each prospect in terms of current market dynamics, potential corporate synergies and expected market potential to streamline our list to the most viable candidates. Through this, we are able to pursue only the most sensible and compelling partnerships. Involving senior management early in the process affords us the flexibility and agility to make timely decisions and innovative licensing or partnering structures that creates winning situations for both companies.



Duke University, MVP and Bio-Technology General/Ferring

Savient licensed exclusive, worldwide rights to the technologies related to Puricase from Duke University ("Duke") of North Carolina and Mountain View Pharmaceuticals, Inc. ("MVP"), a California corporation. Duke developed the recombinant porcine uricase enzyme and MVP developed the PEGylation technology. MVP and Duke were granted U.S. and foreign patents covering the licensed technology. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

Savient has an agreement in place with Bio-Technology General, Ltd., a subsidiary of Ferring B.V. of Switzerland, for the Phase 3 clinical and commercial supply for Puricase.

Watson Supply Agreement

Savient has an agreement in place to supply an A-B rated generic of oxandrolone tablets, (USP) C III, an Oxandrin® brand equivalent product in both the 2.5 mg and 10 mg doses to Watson Pharmaceuticals.
Revenir en haut Aller en bas
ristic



Nombre de messages : 124
Age : 68
Localisation : FOURAS 17
Date d'inscription : 07/09/2008

MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 13:31

Trop fort Simis, Bravo et merci
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
laurent



Nombre de messages : 339
Age : 48
Localisation : PARIS
Date d'inscription : 16/09/2007

MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 13:49

bravo simis

toujours aussi genial
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
vinsse



Nombre de messages : 515
Date d'inscription : 15/05/2008

MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 13:51

Un autre point commun....

William B. White, MD

Dr. White has indicated that he served as a consultant for Astellas
Pharma, Inc., Gilead Sciences, Inc., NicOx, Roche Laboratories Inc.,
Savient
Pharmaceuticals, Inc., Pharmaceuticals, Inc., and Takeda
Pharmaceuticals North America, Inc. He served on the Speaker’s Bureau
for Boehringer Ingelheim Pharmaceuticals, Inc., Forest Laboratories,
Inc. He also received grants/research support from National Institutes
of Health, Novartis Pharmaceuticals Corporation.

In late November 2008, the Company engaged an experienced
independent panel of clinical experts, headed by Dr. William B. White,
Professor of Medicine, Calhoun Cardiology Center, School of Medicine,
to perform a formal blinded and unblinded post-hoc adjudication of all
cardiovascular events included in reports of Serious Adverse Events,
Infusion Reactions and Severe Infusion Reactions from the Phase 3
pegloticase trials. The primary event evaluation was predicated on the
Anti-Platelet Trialist Collaborative (APTC) assessment criteria. This
is a standardized approach that the FDA has widely accepted as a method
of evaluating cardiovascular risk. APTC cardiovascular events include
deaths, nonfatal myocardial infarction or nonfatal stroke. Dr. White
and his panel concluded that:
In addition to the work of Dr. White and his team, a separate
external panel of experts performed an additional analysis by reviewing
"all cause" mortality in the Phase 3 trials and Open Label Extension
study. It is important to note that in the Phase 3 trials, there was a
2:2:1 randomization used, meaning that 4 times as many patients were on
drug than placebo. However, in the Open Label Extension study virtually
all patients were on drug with only 2 going on observation. The panel
determined the following:
Upon review of these amendments, the FDA determined that the
additional information contained in these submissions constituted a
major amendment to the pegloticase BLA, which allowed the FDA under the
Prescription Drug User Fee Act (PDUFA) regulations to extend the review
period. In order to allow the agency time to consider these amendments,
the FDA has notified the Company that the pegloticase BLA priority
review PDUFA action date has been extended by three months to July 30,
2009. Given the extended action date, the FDA has also notified the
Company that the Advisory Committee meeting previously scheduled for
March 5, 2009 will be rescheduled. Savient will provide additional
details regarding the rescheduling of the Advisory Committee meeting
when a specific date and time have been determined.
"While we are eager to move the process forward as quickly as
possible, the change in schedule does not impact our planning related
to commercialization. The Company has always had a commercialization
launch plan that parallels the FDA review process and that will be
adjusted to meet the new PDUFA date," said Hamelin.
Krystexxa as a tradename was found to be acceptable by both the FDA and The European Medicines Agency (EMEA).
The Company will host a conference call and webcast today, Thursday,
February 12, 2009, 2009 at 7:00 PM ET to discuss the status of the BLA
and the amendments filed with the FDA. A question and answer period
will follow the Company's prepared remarks. Both the live and archived
web cast can be accessed from the Investor Relations page of Savient's website at http://www.savient.com.
A digital recording of the web cast will be available within two
hours following the conclusion of the call and will be available for 14
days. To access the recording, use the Dial-In Number and the
Conference ID listed below.
Dial: (888) 802-8577 (U.S. participants) or (973) 935-8754 (International participants).
Conf ID: 85467097
Krystexxa (pegloticase) (formerly referred to as Puricase(R)) is a
pegylated recombinant mammalian urate oxidase in development to control
hyperuricemia and its clinical consequences in patients for whom
conventional therapy is contraindicated or has been ineffective. The
two Phase 3 pivotal trials assessed the safety and efficacy of a
six-month course of pegloticase therapy in patients with
treatment-failure gout, under the auspices of an SPA
from the FDA. Savient has licensed exclusive worldwide rights to the
technology related to Krystexxa (pegloticase) from and Mountain View
Pharmaceuticals, Inc. Puricase(R) is a registered trademark of Mountain
View Pharmaceuticals, Inc.


t'as d'autres suspects Marino ?


Dernière édition par vinsse le Dim 17 Jan - 14:08, édité 1 fois
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
JeanCox



Nombre de messages : 1008
Age : 63
Date d'inscription : 19/12/2007

MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 13:57

Merci Simis, avec Laurent vous êtes de sacrés fouineurs
NB : J'ai oublié Vinsse dans les "fouineurs", plates excuses...

Pour ma part, en faisant quelques recherches, j'ai trouvé que Savient commercialise déjà l'Oxandrin aux US.
C'est un dérivé de testostérone synthétique qui est utilisé pour contrer les pertes de poids involontaires après chirurgie importante, traumas sévères, infections ....C'est le seul produit agréé pour cela.
Lien : http://www.savientpharma.com/products/index.asp

Le produit en phase III est le Puricase (anciennement pegloticase), pour le traitement de la goutte.
Lien : http://www.savientpharma.com/pipeline/pegloticase.asp
Ce produit est déjà licencié à deux reprises.

Je n'ai par contre trouvé aucune référence en rhumato.
Pourrais-tu donner un lien ?

Et je n'ai pas trouvé non plus de références quant à la taille de Savient, ceci pour essayer de comprendre quel genre de "collaboration" il pourrait éventuellement y avoir, si un jour il y en avait une ???

Bon dimanche


Dernière édition par JeanCox le Dim 17 Jan - 14:18, édité 1 fois
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Invité
Invité



MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 14:09

au niveau bourse 3.45/16.62 (ok FDA fait du bien au cours !)
66 millions d'actions CB 930 millions $ :

13.95 -0.33 (-2.31%)
After Hours: 13.95 0.00 (0.00%)
Jan 15, 5:15PM EST
NASDAQ real-time data - Disclaimer
Range 13.85 - 14.37
52 week 3.45 - 16.62
Open 14.33
Vol / Avg. 681,190.00/1.03M
Mkt cap 929.44M
P/E -
Div/yield -
EPS -2.01
Shares 66.63M

au niveau rhumato ils parlent de produits de niche :

Savient Pharmaceuticals is a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical products that target unmet medical needs in rheumatology and other specialty niche medical markets. Our focus is on our novel biologic product candidate, Puricase® (pegloticase) that has been developed for treatment-failure gout (TFG).
Revenir en haut Aller en bas
JeanCox



Nombre de messages : 1008
Age : 63
Date d'inscription : 19/12/2007

MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 14:14

Ok Marino, j'ai sans doute lu un peu vite et n'ai pas vu le terme rheumatology


Penses-tu qu'une collaboration ou rapprochement serait envisageable ?
Et dans ce cas, notre chère Jennifer (comme tu l'appelles) servirait de trait d'union ?
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Invité
Invité



MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 14:27

bonjour Jean, je me contente de supposer car on a pas grand chose à se mettre sous la dent ... Jennifer est une spécialiste du marketing pour lancer un produit, j'imagine que c'est elle qui s'est occupé de ça pour l'Oxandrin , peut-être NicOx les a approché avant le OK FDA et que ça ne c'est pas fait mais ils auraient pu recruter à ce moment-là Jennifer Collins ...

que d'hypothèses Cox nous aura donné à manger ...


Dernière édition par simis le Dim 17 Jan - 17:18, édité 1 fois
Revenir en haut Aller en bas
Invité
Invité



MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 14:31

pour Vinsse :

d'autres suspects :

Anesiva / Omeros / Adolor
Revenir en haut Aller en bas
Invité
Invité



MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 16:54

merci,trop gros pour etre manger par nicox dorenavant , capi 2 fois superieur par contre dommage qu'il n'est pas tiré a 3.5$ mi 2009..on aurait compris en tant qu'actionnaire..c'etait vraiment une belle cible.

autres observations ,il pourrait y avoir fusion apres accord fda.
style 1/1 action mais c plus hypothetique.
Revenir en haut Aller en bas
julestot



Nombre de messages : 138
Age : 41
Localisation : sud belgique
Date d'inscription : 23/03/2007

MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   Dim 17 Jan - 23:02

Hello,

Petite remarque sur jennifer collins; Dans ces jobs précédents, elle était:

Marketing Communications Manager--Xalatan at

Pharmacia.

Le Xalatan, tiens tiens Wink
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Contenu sponsorisé




MessageSujet: Re: nouvelle embauche chez NicOx ! Jennifer Collins Associate Br   

Revenir en haut Aller en bas
 
nouvelle embauche chez NicOx ! Jennifer Collins Associate Br
Voir le sujet précédent Voir le sujet suivant Revenir en haut 
Page 1 sur 1
 Sujets similaires
-
» Une nouvelle de plus chez les Moms!!
» Nouvelle à Thonon!!
» Nouvelle venue dans le monde des Mampreneurs
» bonne nouvelle
» nouvelle campagne ricoré (16/09)

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
AMicale des COXiens :: Forum public :: Echanges sur NicOx-
Sauter vers: